Corporate Banner
Satellite Banner
Technology Networks Header
Monday, November 24, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Molecular Event Mapping Opens Door to more in silico Tests
It is hoped that this new approach to mapping and predicting the impact of chemical compounds in the body could reduce the need for toxicity tests in animals.
Protein-engineered Cages Aid Studies of Cell Functions
The Cages, from researchers at Tokyo Institute of Technology, to deliver an important signalling molecule, carbon monoxide, into cells.
Wallet-Sized Labs The Next Big Thing
RMIT researchers are developing inexpensive, portable toxicology laboratories so small you could fit them in your wallet.
Altered Milk Protein Can Deliver AIDS Drug to Infants
Binding with an antiretroviral drug promises to greatly improve treatment for infants and young children suffering from HIV/AIDS.
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
Immunotherapy for Cancer Toxic with Obesity
UC Davis researchers link increased body fat and lethal drug reactions in mice.
An Unlikely Use for Diamonds
Tiny diamonds provide new possibilities for accurate measurements of processes inside living cells with potential to improve drug delivery and cancer therapeutics.
Microscopic “Walkers” Find Their Way Across Cell Surfaces
Technology could provide a way to deliver probes or drugs to cell structures without outside guidance.
Revalesio’s Drug Shows Promise in Treating Alzheimer’s
Multiple published research studies outline the potential for RNS60 to effectively treat Alzheimer’s disease by protecting neuronal function and restoring neuronal plasticity.
Getting Metabolism Right
Analysis of 89 models of metabolic processes finds flaws in 44 of them — but suggests corrections.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv